Weight-Loss shot tested as potential breakthrough for dual diagnosis of schizophrenia and alcoholism
NCT ID NCT06939088
Summary
This study is testing whether a weekly injection called tirzepatide, currently used for diabetes and weight loss, can help reduce heavy alcohol use in people who also have schizophrenia. About 108 participants will receive either the real drug or a placebo (dummy injection) for 26 weeks, while also getting supportive therapy. Researchers will track drinking habits and use brain scans in some participants to see if the drug changes how the brain responds to alcohol cues.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Psychiatry, Aalborg University Hospital
RECRUITINGAalborg, Denmark, 9000, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Psychiatric Center Copenhagen, Frederiksberg Hospital
RECRUITINGFrederiksberg, Denmark, 2100, Denmark
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.